Industry

RxSight, Inc. Reports First Quarter 2026 Results and Reiterates Full-Year Sales Outlook

Vision Monday2d ago1 min read

ALISO VIEJO, Calif.—RxSight, Inc. (NASDAQ: RXST), an ophthalmic medical device company focused on improving vision after cataract surgery, on Wednesday announced financial results for the quarter ended March 31, 2026. In the first quarter of 2026, the company reported sales of $30.9 million, down 18.5 percent compared with the same period in 2025, which RxSight said is largely reflective of lower light delivery device (LDD) unit volumes, consistent with expectations. Light adjustable lens (LAL) procedures decreased 0.4 percent year over year, the company advised.

Read full article on Vision Monday

AI Summary

Quick Take

RxSight reported Q1 2026 revenue of $30.9 million, an 18.5% decrease from the same period in 2025, primarily due to a planned reduction in Light Delivery Device (LDD) unit sales. Despite the drop in capital equipment revenue, Light Adjustable Lens (LAL) procedure volumes remained remarkably stable, dipping only 0.4% year-over-year.

Why It Matters

The financial results suggest RxSight is transitioning from a phase of aggressive capital equipment placement to a more mature model focused on procedure volume. For the surgical community, the steady LAL procedure numbers indicate that the technology has maintained its clinical foothold even as new device installations slow down. This stability is a key indicator of the long-term viability of post-operative adjustable optics in the premium IOL market, as the existing user base continues to utilize the platform at consistent rates.

Key Details

Total sales for Q1 2026 were $30.9 million, down from the $37.9 million reported in Q1 2025.
The 18.5% revenue decline was largely attributed to lower unit volumes of the Light Delivery Device (LDD).
Light Adjustable Lens (LAL) procedure volume showed high resilience, with only a marginal 0.4% decrease year-over-year.
The company reiterated its full-year sales outlook for 2026, suggesting confidence in performance for the remaining three quarters.
Management stated the lower LDD volumes were consistent with their internal expectations for the start of the year.

Practice Implications

Practice owners and refractive surgeons should view these results as a sign of market stabilization for adjustable lens technology. While the rapid expansion of new LDD installations may be cooling, the consistent procedure volume suggests that the clinical workflow and patient demand for LALs remain a reliable component of premium cataract surgery offerings.

Who's Affected

Cataract SurgeonsRefractive SurgeonsPractice OwnersOphthalmic Administrators

What's Next

RxSight has reiterated its full-year sales outlook, indicating that the company expects revenue to align with previous projections despite the Q1 dip. Stakeholders should watch for whether LAL procedure volumes return to growth in Q2 and Q3 to offset the decrease in capital equipment sales.

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.